loader
Please Wait
Applying Filters...

Seqens Seqens

X

Approved Drug Products containing 213491 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Left Arrow
Right Arrow
Filters Filter
Cross PopUp
FILTER :

filter

01 HORIZON (2)

filter

01 GRANULE, DELAYED RELEASE;ORAL (2)

filter

01 RX (2)

filter

01 PROCYSBI (2)

filter

01 Yes (2)

URL Supplier Web Content
GRANULE, DELAYED R...
EQ 300MG BASE/PACK...
2020-02-14
213491
PROCYSBI
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
GRANULE, DELAYED R...
EQ 75MG BASE/PACKE...
2020-02-14
213491
PROCYSBI
RX
Yes
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for FDA Orange Book APPLICATION 213491

Looking for FDA Orange Book APPLICATION 213491 2

19

Horizon Therapeutics, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is CYSTEAMINE BITARTRATE, with a corresponding application number 213491.

Regulatory Information RX

With a dosage strength EQ 300MG BASE/PACKET

Dosage Form Route GRANULE, DELAYED RELEASE; ORAL

Reference Listed Drug Yes

Approved since 2020-02-14

18

Horizon Therapeutics, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is CYSTEAMINE BITARTRATE, with a corresponding application number 213491.

Regulatory Information RX

With a dosage strength EQ 75MG BASE/PACKET

Dosage Form Route GRANULE, DELAYED RELEASE; ORAL

Reference Listed Drug Yes

Approved since 2020-02-14

Post Enquiry
POST ENQUIRY